Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

NCT02601209 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

151

Enrollment

NIH

Sponsor class

Stopped Interim monitoring

Conditions

High Grade Sarcoma
Metastatic Leiomyosarcoma
Metastatic Malignant Peripheral Nerve Sheath Tumor
Metastatic Synovial Sarcoma
Metastatic Undifferentiated Pleomorphic Sarcoma
Metastatic Unresectable Sarcoma
Myxofibrosarcoma
Recurrent Leiomyosarcoma
Recurrent Malignant Peripheral Nerve Sheath Tumor
Recurrent Synovial Sarcoma
Recurrent Undifferentiated Pleomorphic Sarcoma
Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8
Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8
Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8
Stage IV Uterine Corpus Leiomyosarcoma AJCC v8
Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8
Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
Unresectable Leiomyosarcoma

Interventions

DRUG: Pazopanib
DRUG: Pazopanib Hydrochloride
DRUG: Sapanisertib

Sponsor

National Cancer Institute (NCI)